OFFICIALS LEGISLATION INTEREST GROUPS PUBLIC STATEMENTS COMMITTEES VETOES

Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018

Floor Speech

Date: March 13, 2018
Location: Washington, DC
Issues: Health and Health Care

BREAK IN TRANSCRIPT

Mr. CARTER of Georgia. Mr. Speaker, I rise today in support of the Right to Try Act because this legislation will improve access to potentially lifesaving treatments for patients with terminal diseases or conditions.

Currently, patients can only receive drugs that are undergoing FDA review through clinical trials, through compassionate use, or expanding access. They access these unapproved treatments exclusively through the FDA but not through the drug sponsor. This critical legislation would establish informed consent for patients to access unapproved drugs that could save their lives.

This bill still guards patients from manufacturers misbranding or mislabeling drugs and specifies that any unapproved drug used in the alternative pathway must have an active application and is not the subject of a clinical hold.

I thank my good friend Chairman Burgess and the rest of my colleagues on the committee for moving this legislation forward and working with the administration and stakeholders on all sides of these issues. This is a great step forward towards ensuring our patients get to take advantage of the incredible pharmaceutical therapies that our manufacturers are known for.

I applaud the Energy and Commerce Committee for their work in moving this legislation forward, and I urge my colleagues to support this legislation.

BREAK IN TRANSCRIPT


Source
arrow_upward